相关实验视频

Updated: Jun 16, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

准c-MYC在肝细胞癌治疗中起着关键作用

Peng Dai¹, Liping Wang²

¹Comprehensive Internal Medicin，Shanxi Province Cancer Hospital/ Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Shan Xi Taiyuan, 030001, China.

Critical reviews in oncology/hematology

|June 5, 2025

概括

肝细胞癌 (HCC) 是一种致命的癌症. 瘤转录因子c-MYC通过改变细胞过程和新陈代谢来驱动HCC. 针对c-MYC提供了有前途的新HCC治疗策略.

科学领域:

肝病学肝病学是一种肝病学.
在瘤学瘤学.
分子生物学分子生物学

背景情况:

肝细胞癌 (HCC) 是全球癌症死亡的主要原因,其治疗选择有限.
转录因子c-MYC是HCC的一个关键驱动因素,影响扩散,新陈代谢和亡.
失调的c-MYC活性与异常的信号通路 (PI3K/Akt/mTOR,Wnt/β-catenin,MAPK/ERK) 相关,促进瘤的进展.

研究的目的:

提供对c-MYC驱动的肝癌发生背后的分子机制的全面审查.
探索针对c-MYC和HCC治疗相关途径的新兴治疗策略.

主要方法:

在HCC中对c-MYC功能研究的文献综述.
对信号通路,代谢重编程和涉及c-MYC的表观遗传相互作用的分析.
检查针对c-MYC的当前和潜在的治疗干预措施.

主要成果:

c-MYC失调是HCC发病的核心,促进不受控制的细胞生长和改变的新陈代谢 (糖解,谷氨酸代谢).
c-MYC,表观遗传修饰剂,无化和非编码RNA之间的相互作用维持其致癌功能.
多个信号通路在c-MYC的下游异常激活,导致瘤进展.

结论:

针对c-MYC,直接或通过途径调制和组合疗法,为HCC提供了一个有前途的治疗途径.
更深入地了解c-MYC在HCC中的多方面的作用对于开发新和有效的临床治疗至关重要.

关键词:

在C-MYC中.药物耐药性药物耐药性药物耐药性在HCC中,HCC是HCC.肝细胞癌是肝细胞癌.肝癌是一种肝癌.有针对性的治疗.转录因子是一种转录因子.

更多相关视频

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Induced Pluripotent Stem Cells

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...